Bluejay Diagnostics (BJDX)

Executive Summary

Bluejay Diagnostics is a U.S.-based medical diagnostics company developing the Symphony platform, a rapid, portable point-of-care blood testing system that delivers laboratory-comparable results in approximately 20 minutes. The company's lead product is an IL-6 assay targeting sepsis triage and acute systemic inflammation monitoring. As a publicly traded entity (NASDAQ: BJDX) with a current valuation of ~$1.8M, Bluejay is focused on completing development and obtaining regulatory clearances for its Symphony IL-6 test. The platform is designed for future expansion to other biomarkers. Despite being early-stage with no commercial products yet, the company addresses a significant unmet need for rapid, accurate sepsis diagnostics, which could improve patient outcomes and reduce healthcare costs. However, the company faces typical development and regulatory risks, and its path to market is uncertain.

Upcoming Catalysts (preview)

• H2 2026FDA submission or clearance for Symphony IL-6 test25% success
• 2026Partnership or licensing agreement for commercialization30% success
• H1 2027Clinical study results or data readout for IL-6 assay40% success